



ASX RELEASE

ASX Code: ESE

16 April 2019

eSense-Lab Receives First E-Juice Order for Retail Distribution in USA and Canada

Investment highlights:

- Received first order of e-juice product for distribution in the USA and Canada
- The order was made under an agreement with VaporSpec, a California-based vaping distributor
- The agreement calls for minimum quantities of 450,000 bottles of e-juice in the first year, rising to 5 million bottles in Year 3 of the agreement
- eSense is continuing to accelerate its global commercialisation strategy

Life science company **eSense-Lab Ltd** ("**eSense**" or the "**Company**") (**ASX:ESE**) is pleased to announce that it had received the first order of its e-juice product for distribution in the USA and Canada.

The order was made in accordance with the commercial non-exclusive distribution agreement for the supply of e-Juice to VaporSpec Inc. ("VaporSpec") (www.vaporspec.biz), a California-based company distributing products to the vaping industry.

The initial order is for several hundreds of bottles of various e-juice flavours to be distributed to various end user commercial retail distributors and points of sale. Further order are expected within the next few weeks.

The Company announced the distribution agreement with VaporSpec in Q1 CY19 [ASX Announcement: February 7, 2019]. The agreement calls for minimum quantities of e-Juice to be supplied in 10 ml. bottles. Minimum annual quantities rise from 450,000 bottles in the first year to 5 million bottles in Year 3 of the agreement.

VaporSpec is a premier distributor of products to both the wholesale and retail vaping markets. E-liquids are used for vaporising or "vaping" and are a safer alternative to smoking. The agreement with Vaporspec further demonstrates eSense's accelerating commercialisation strategy, following a similar agreement signed with a UK-based entity [ASX Announcement: 6 December 2018].

eSense's CEO Haim Cohen said: "We are extremely pleased to receive our first order of the Company's product for distribution in the North American vaping market. This deal is under the agreement eSense has signed with VaporSpec, which has a significant market share of California's vaping market. We continue to commercialise our terpenes, and penetration of the global e-liquid market is proving successful, as evidenced by this most recent distribution agreement. We are also in the process of commercialising our products to the food additive, food supplements, e-cigarette and other related markets, as well as continuing the development of medicinal cannabis products."

ENDS



For further information, please contact:

Chairman

Piers Lewis

+61 409 374 893

piers@smallcapcorporate.com.au

Media & Investor Enquiries

Julia Maguire

+61 419 815 386

julia@thecapitalnetwork.com.au

Corporate Advisor

EverBlu Capital

+61 2 8249 0000

info@everblucapital.com

About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit www.esense-lab.com